| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/19/2004 | WO2003049683A3 Use of parapox b2l protein to treat cancer and modify immune responses |
| 02/19/2004 | WO2003048780A3 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis |
| 02/19/2004 | WO2003048193A3 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 02/19/2004 | WO2003037265A9 Method of treating viral infections |
| 02/19/2004 | WO2003035104B1 Compositions and methods for selected tumor treatment |
| 02/19/2004 | WO2003033520A3 Anticancer vaccine and diganostic methods and reagents |
| 02/19/2004 | WO2003032907A3 High-concentration protein formulations and method of manufacture |
| 02/19/2004 | WO2003027291A3 Hdv nucleic acid molecules, fragments and applications thereof |
| 02/19/2004 | WO2003020212A3 Treatment for central nervous system disorders |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2003010291A3 Treatment of immune disorders and b cell disorders |
| 02/19/2004 | WO2003008537A9 Epitope sequences |
| 02/19/2004 | WO2003000113A9 Compositions and methods for the diagnosis and treatment of tumor |
| 02/19/2004 | WO2002097072A8 Influenza vaccine composition |
| 02/19/2004 | WO2002086101A3 Core-glycosylated hcv envelope proteins |
| 02/19/2004 | WO2002086100A3 Expression of core-glycosylated hcv envelope proteins in yeast |
| 02/19/2004 | WO2002083866A3 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| 02/19/2004 | WO2002081496A3 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
| 02/19/2004 | WO2002079231B1 Nucleic acids encoding isav polypeptides |
| 02/19/2004 | WO2002078736A3 Antiallergic pharmaceutical composition |
| 02/19/2004 | WO2002078613A3 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response |
| 02/19/2004 | WO2002074251A3 Monoclonal antibody therapy for pancreas cancer |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002028888A3 Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034209 Using genetic vaccine to treat and prevent infection by lymphadenopathy associated virus; viricides |
| 02/19/2004 | US20040033594 Comprises RNA viral sequences for use in development of diagnostics and genetic vaccines against viral infection |
| 02/19/2004 | US20040033586 Pasteurella and/or actinobacillus mutant coding polypeptide for prevention and treatment of infectious disease; veterinary medicine |
| 02/19/2004 | US20040033585 Preparing tobbaco mosaic viral particles comprising therapeutic polypeptides for treatment of infectious diseases and tumors; immunotherapy; genetic vaccines |
| 02/19/2004 | US20040033550 Method of isolating biologically active fraction containing clinically acceptable native S-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides |
| 02/19/2004 | US20040033535 Antibodies to OPGL |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033519 Binary or polynary targeting and uses thereof |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033491 Proteins and nucleic acids encoding same |
| 02/19/2004 | US20040033487 Comprises nucleotide sequences coding associated with glycosylation of viral structural polypeptides; prototype immunogens for treatment and prevention of viral disease; genetic vaccines |
| 02/19/2004 | US20040033486 Comprises peptide nucleic acid for immunizing animal and human subjects against bacterial, viral, parasitic, fungal and cancers; genetic vaccines |
| 02/19/2004 | US20040033240 Immunological combinations for prophylaxis and therapy of helicobacter pylori infection |
| 02/19/2004 | US20040033239 Adenovirus formulations |
| 02/19/2004 | US20040033238 Selectable genetic marker for use in pasteurellaceae species |
| 02/19/2004 | US20040033237 Immunogenicity using a combination of dna and vaccinia virus vector vaccines |
| 02/19/2004 | US20040033236 Recombinant constructs of borrelia burgdorferi |
| 02/19/2004 | US20040033235 Inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells. |
| 02/19/2004 | US20040033233 Dried powder form in sachet or in capsule of root, bark and wood of Philippine Narra tree (Pterocarpus Indicus) |
| 02/19/2004 | US20040033231 First domain comprising a PP14 polypeptide sequence and a second domain comprising a polypeptide sequence of the Fc region of an immunoglobulin protein; treatment of immune system diseases and disorders |
| 02/19/2004 | US20040033230 Breast tumor polypeptides, polynucleotides that encode them, antigen presenting cells that express them, and T cells that are specific for cells that express them. |
| 02/19/2004 | US20040033229 PSMA antibodies and protein multimers |
| 02/19/2004 | US20040033211 Antigen arrays for treatment of bone disease |
| 02/19/2004 | US20040033210 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 02/19/2004 | CA2818693A1 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | CA2759572A1 Isolation and identification of t cells |
| 02/19/2004 | CA2497662A1 Pharmaceutical compositions comprising an hiv envelope protein and cd4 |
| 02/19/2004 | CA2497448A1 Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions |
| 02/19/2004 | CA2495456A1 Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof |
| 02/19/2004 | CA2495121A1 Nogo receptor antagonists |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494911A1 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | CA2494844A1 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | CA2494742A1 Tiacumicin production |
| 02/19/2004 | CA2494675A1 Immunomodulating compositions, processes for their production and uses therefor |
| 02/19/2004 | CA2494319A1 Use of antibodies against a tumor-associated antigen |
| 02/19/2004 | CA2494252A1 Psmcs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | CA2494236A1 Csnk1gs as modifiers of the p21 pathway and methods of use |
| 02/19/2004 | CA2494193A1 Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes |
| 02/19/2004 | CA2494192A1 Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes |
| 02/19/2004 | CA2494108A1 Amyloid immunization and cox-2 inhibitors for the treatment of alzheimer's disease |
| 02/19/2004 | CA2493977A1 Vaccine composition comprising lipooligosaccharide with reduced phase variability |
| 02/19/2004 | CA2493908A1 Thiophene compounds |
| 02/19/2004 | CA2493124A1 Vaccine |
| 02/19/2004 | CA2493092A1 Neisserial vaccine compositions comprising a combination of antigens |
| 02/19/2004 | CA2489301A1 Vaccinia virus host range genes to increase the titer of avipoxviruses |
| 02/19/2004 | CA2489030A1 Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
| 02/18/2004 | EP1389304A1 Adherent entities and uses therefor |
| 02/18/2004 | EP1389233A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/18/2004 | EP1389137A2 Compositions for protein delivery via the pulmonary route |
| 02/18/2004 | EP1389108A2 Methods for selective immunomodulation using pimecrolimus |
| 02/18/2004 | EP1389043A1 Foot and mouth disease virus vaccine |
| 02/18/2004 | EP1237408B1 Pour-on formulations |
| 02/18/2004 | EP1178822B1 Whole cell cancer vaccine comprising co-cultured malignant and non-malignant cells |
| 02/18/2004 | EP0967995B1 Composition comprising immunoglobulin |
| 02/18/2004 | EP0817851B1 Dna encoding human papilloma virus type 18 |
| 02/18/2004 | EP0791064B1 Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines |
| 02/18/2004 | EP0731838B1 Binding structures directed against the ca55.1 antigen |
| 02/18/2004 | CN1476483A Modified vaccinia ankara virus variant |
| 02/18/2004 | CN1476480A Isolated peptides which bind to HLA-C molecules and uses thereof |
| 02/18/2004 | CN1475571A Expression of recombination SARS virus gene in pleiomorphic Hansen yeast and its use |
| 02/18/2004 | CN1475498A Preparation of antigen sensitized human dendron shaped cell and its use |
| 02/18/2004 | CN1138859C Infection clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| 02/18/2004 | CN1138786C Antibody for identifying osteoclast forming inhibitor binding protein, and preparing process and use |
| 02/18/2004 | CN1138591C Coated particles, method of making and using |
| 02/18/2004 | CN1138564C Influenza vaccine |
| 02/18/2004 | CN1138563C Vector for diagnosis and treatment of solid tumors including melanoma |
| 02/18/2004 | CN1138562C Use of muteins of wild-type cytokines as immunogens |
| 02/18/2004 | CN1138533C Liposomes |
| 02/17/2004 | WO2004076645A3 Compositions and methods for cytomegalovirus treatment |
| 02/17/2004 | US6693186 Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof |
| 02/17/2004 | US6693183 MURINE α (1,3) FUCOSYLTRANSFERASE FUC-TVII, DNA ENCODING THE SAME, METHOD FOR PREPARING THE SAME, ANTIBODIES RECOGNIZING THE SAME, IMMUNOASSAYS FOR DETECTING THE SAME, PLASMIDS CONTAINING SUCH DNA, AND CELLS CONTAINING SUCH A PLASMID |
| 02/17/2004 | US6693087 Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| 02/17/2004 | US6693086 Eliciting nonantigen and strong antigen specific immune response; cancer, allergic inflammation and/or infectious disease prevention |